Selected research
Industry Research
Repurposed Drugs Industry Research Report 2026
Market perspective
The global Repurposed Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Repurposed Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Repurposed Drugs market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Repurposed Drugs market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Repurposed Drugs include Teva, Johnson & Johnson, Novartis, Mylan, Pfizer, GSK, R-Pharma, Glenmark and Fujifilm, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Repurposed Drugs market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Repurposed Drugs.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Repurposed Drugs Market by Company
Teva
Johnson & Johnson
Novartis
Mylan
Pfizer
GSK
R-Pharma
Glenmark
Fujifilm
Dr. Reddy
ChemRar Group
Bausch Health
Repurposed Drugs Segment by Type
Generic Drugs
Clinical Trial Failed Drugs
Repurposed Drugs Segment by Application
Cardiovascular Diseases
Mental Illness
Cancer
Other
Repurposed Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Repurposed Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Repurposed Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Repurposed Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Repurposed Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Generic Drugs
- Clinical Trial Failed Drugs
Applications
- Cardiovascular Diseases
- Mental Illness
- Cancer
- Other
Companies covered
- Teva
- Johnson & Johnson
- Novartis
- Mylan
- Pfizer
- GSK
- R-Pharma
- Glenmark
- Fujifilm
- Dr. Reddy
- ChemRar Group
- Bausch Health
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Repurposed Drugs by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Generic Drugs
- 2.2.3 Clinical Trial Failed Drugs
- 2.3 Repurposed Drugs by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Cardiovascular Diseases
- 2.3.3 Mental Illness
- 2.3.4 Cancer
- 2.3.5 Other
- 2.4 Assumptions and Limitations
3 Repurposed Drugs Breakdown Data by Type
- 3.1 Global Repurposed Drugs Historic Market Size by Type (2021-2026)
- 3.2 Global Repurposed Drugs Forecasted Market Size by Type (2027-2032)
4 Repurposed Drugs Breakdown Data by Application
- 4.1 Global Repurposed Drugs Historic Market Size by Application (2021-2026)
- 4.2 Global Repurposed Drugs Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Repurposed Drugs Market Perspective (2021-2032)
- 5.2 Global Repurposed Drugs Growth Trends by Region
- 5.2.1 Global Repurposed Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Repurposed Drugs Historic Market Size by Region (2021-2026)
- 5.2.3 Repurposed Drugs Forecasted Market Size by Region (2027-2032)
- 5.3 Repurposed Drugs Market Dynamics
- 5.3.1 Repurposed Drugs Industry Trends
- 5.3.2 Repurposed Drugs Market Drivers
- 5.3.3 Repurposed Drugs Market Challenges
- 5.3.4 Repurposed Drugs Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Repurposed Drugs Players by Revenue
- 6.1.1 Global Top Repurposed Drugs Players by Revenue (2021-2026)
- 6.1.2 Global Repurposed Drugs Revenue Market Share by Players (2021-2026)
- 6.2 Global Repurposed Drugs Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Repurposed Drugs Head Office and Area Served
- 6.4 Global Repurposed Drugs Players, Product Type & Application
- 6.5 Global Repurposed Drugs Manufacturers Established Date
- 6.6 Global Repurposed Drugs Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Repurposed Drugs Market Size (2021-2032)
- 7.2 North America Repurposed Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Repurposed Drugs Market Size by Country (2021-2026)
- 7.4 North America Repurposed Drugs Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Repurposed Drugs Market Size (2021-2032)
- 8.2 Europe Repurposed Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Repurposed Drugs Market Size by Country (2021-2026)
- 8.4 Europe Repurposed Drugs Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Repurposed Drugs Market Size (2021-2032)
- 9.2 Asia-Pacific Repurposed Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Repurposed Drugs Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Repurposed Drugs Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Repurposed Drugs Market Size (2021-2032)
- 10.2 South America Repurposed Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Repurposed Drugs Market Size by Country (2021-2026)
- 10.4 South America Repurposed Drugs Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Repurposed Drugs Market Size (2021-2032)
- 11.2 Middle East & Africa Repurposed Drugs Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Repurposed Drugs Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Repurposed Drugs Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva
- 12.1.1 Teva Company Information
- 12.1.2 Teva Business Overview
- 12.1.3 Teva Revenue in Repurposed Drugs Business (2021-2026)
- 12.1.4 Teva Repurposed Drugs Product Portfolio
- 12.1.5 Teva Recent Developments
- 12.2 Johnson & Johnson
- 12.2.1 Johnson & Johnson Company Information
- 12.2.2 Johnson & Johnson Business Overview
- 12.2.3 Johnson & Johnson Revenue in Repurposed Drugs Business (2021-2026)
- 12.2.4 Johnson & Johnson Repurposed Drugs Product Portfolio
- 12.2.5 Johnson & Johnson Recent Developments
- 12.3 Novartis
- 12.3.1 Novartis Company Information
- 12.3.2 Novartis Business Overview
- 12.3.3 Novartis Revenue in Repurposed Drugs Business (2021-2026)
- 12.3.4 Novartis Repurposed Drugs Product Portfolio
- 12.3.5 Novartis Recent Developments
- 12.4 Mylan
- 12.4.1 Mylan Company Information
- 12.4.2 Mylan Business Overview
- 12.4.3 Mylan Revenue in Repurposed Drugs Business (2021-2026)
- 12.4.4 Mylan Repurposed Drugs Product Portfolio
- 12.4.5 Mylan Recent Developments
- 12.5 Pfizer
- 12.5.1 Pfizer Company Information
- 12.5.2 Pfizer Business Overview
- 12.5.3 Pfizer Revenue in Repurposed Drugs Business (2021-2026)
- 12.5.4 Pfizer Repurposed Drugs Product Portfolio
- 12.5.5 Pfizer Recent Developments
- 12.6 GSK
- 12.6.1 GSK Company Information
- 12.6.2 GSK Business Overview
- 12.6.3 GSK Revenue in Repurposed Drugs Business (2021-2026)
- 12.6.4 GSK Repurposed Drugs Product Portfolio
- 12.6.5 GSK Recent Developments
- 12.7 R-Pharma
- 12.7.1 R-Pharma Company Information
- 12.7.2 R-Pharma Business Overview
- 12.7.3 R-Pharma Revenue in Repurposed Drugs Business (2021-2026)
- 12.7.4 R-Pharma Repurposed Drugs Product Portfolio
- 12.7.5 R-Pharma Recent Developments
- 12.8 Glenmark
- 12.8.1 Glenmark Company Information
- 12.8.2 Glenmark Business Overview
- 12.8.3 Glenmark Revenue in Repurposed Drugs Business (2021-2026)
- 12.8.4 Glenmark Repurposed Drugs Product Portfolio
- 12.8.5 Glenmark Recent Developments
- 12.9 Fujifilm
- 12.9.1 Fujifilm Company Information
- 12.9.2 Fujifilm Business Overview
- 12.9.3 Fujifilm Revenue in Repurposed Drugs Business (2021-2026)
- 12.9.4 Fujifilm Repurposed Drugs Product Portfolio
- 12.9.5 Fujifilm Recent Developments
- 12.10 Dr. Reddy
- 12.10.1 Dr. Reddy Company Information
- 12.10.2 Dr. Reddy Business Overview
- 12.10.3 Dr. Reddy Revenue in Repurposed Drugs Business (2021-2026)
- 12.10.4 Dr. Reddy Repurposed Drugs Product Portfolio
- 12.10.5 Dr. Reddy Recent Developments
- 12.11 ChemRar Group
- 12.11.1 ChemRar Group Company Information
- 12.11.2 ChemRar Group Business Overview
- 12.11.3 ChemRar Group Revenue in Repurposed Drugs Business (2021-2026)
- 12.11.4 ChemRar Group Repurposed Drugs Product Portfolio
- 12.11.5 ChemRar Group Recent Developments
- 12.12 Bausch Health
- 12.12.1 Bausch Health Company Information
- 12.12.2 Bausch Health Business Overview
- 12.12.3 Bausch Health Revenue in Repurposed Drugs Business (2021-2026)
- 12.12.4 Bausch Health Repurposed Drugs Product Portfolio
- 12.12.5 Bausch Health Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst